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Abstract
Rapid growth of global human population has been implicating to food short-
age, social problems and environmental degradation. Contraceptive devices have 
long been applied as a major method to reduce natality. Current application of this 
technology relies upon hormonal administration, condom, withdrawal and recently 
hormonal vaccino-contraceptive. Discoveries of antisperm proteins have been direct-
ing current researches toward developments of antisperm antibody (ASA) contracep-
tions. Actions of ASA are targeting antigens either on the head or on the tail of sperm. 
Antibodies targeting head antigens aimed at blocking gamete fusion, ZP penetration 
and/or acrosome reaction. Molecules working on sperm tails are aimed to block sperm 
motility or energy production. PCSK4 is one sperm antigen firstly expressed on the 
human sperm acrosome during its initial development on the round spermatid and 
retains on the acrosome until sperm is matured. It is known to contribute to the post-
capacitational hyperactivation of sperm essential for zona penetration. Rat models 
injected with rabbit-anti human PCSK4 developed incompetent sperm and allowance 
of these male rats to fertile female rats resulted significant reduction of conception 
rate. Apart from antibody, synthetic inhibitors of PCSK4 have also been developed. 
Future developments of ASA contraception are discussed.
Keywords: contraception, ASA, PCSK4, synthetic peptide
1. Introduction
The world population had grown enormously during the period of 40 years 
since 1960 to 2000, doubled from 3 to 6.1 billion peoples [1–3]. In 2010, it became 
6.9 billion and was estimated to reach 9.3 billion in 2050 or to increase by 35% from 
that in 2010 [2, 4, 5]. The growth seems slower after 2000 and the global population 
growth in the next decades until 2050 was estimated to be slower by three times 
compared to those during the period of 1960–2000 [1–5].
Despite a slower growth, negative impacts of high human population on envi-
ronment as well as on human have been remaining high. In one hand, the need 
to provide more foods to feed more peoples has triggered environment degrada-
tion through the use of chemical fertilisers, practices of intensified farming and 
farming mechanisations, to boost the amount of yields and frequency of harvests 
[6]. Moreover, increased land uses for housings and agricultures have led further 
environment degradation in tropical regions through deforestation [7]. On the 
other hand, population growth along with poverty was reported to link to further 
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serious social problems and terrorism in some communities [8]. Therefore, efforts 
to further effectively suppress the world population growth needs updated strate-
gies that fits with current issues.
A method that globally has been used as a measure to control birth is contracep-
tive practice. Contraception includes all means to prevent pregnancy resulted from 
an intercourse. Contraceptions currently used widely among women are hormonal 
(pills, blotch and injectable forms), natural (near ovulation abstinence and before 
ejaculation withdrawal), intravaginal or intrauterine (vaginal rings, diaphragm, 
spermicides or intrauterine devices) and sterilisation, while popular men contra-
ceptives are withdrawal method (coitus interruptus), condom and vasectomy [9].
More than 6.5 billion of global population have used at least one contraception 
method, with the increase of new users are of 75 million couples annually [3]. The 
largest number of contraceptive users are women while male contraceptions are 
practiced only by 30% of couples worldwide [3, 9–11]. Existing women contracep-
tive methods however, pose discomforts as well as adverse effects. For example, pills 
have to be taken daily. Interruptions due to some practical reasons such as forgets 
have been commonly heard and would risk its infectivity. Moreover, the hormonal 
pill contraception in selective cases might risk occurrence of venous thrombosis and 
breast cancer [12]. Intra uterine devices are thought to be effective for long term 
usage but some users reported side effects such as bleeding, discomforts, infection 
and pain [13].
Likewise, current male contraceptives utilisation have been known to cause 
several side effects which might have attributed to the low utilisation among men. 
Condom uses cause sexual discomforts and low rate failures have been reported 
(5–15%) [3]. In addition, the application of steroid male contraceptive such as tes-
tosterone enanthate (TE) was reported to cause obesity, testicular atrophy in 25% of 
cases and reduced level of high density lipoprotein (HDL) in 10% of cases [14].
Vasectomy, the vas deferens ligation, is by far the most effective and economi-
cal male contraceptive method and as many as 7% (40–60 million) of worldwide 
couples practice this method [12]. One advantage of vasectomy is, that it can be 
reversed by vasovasostomy surgery to restore fertility with the rate of pregnancy 
after the reversal was between of 30–60% but, the rate decreased when the vasova-
sostomy was performed 8 years after vasectomy was conducted [3]. Fertility restora-
tion and pregnancy rate after vasectomy reversal are influenced by, among others, 
the interval of vasectomy to reversal surgery, the presence of azoospermia, presence 
of sperm granuloma, the age of female partner and the same female partner [15].
Some studies reported the association of vasectomy and prostatic cancers but, 
studies claimed as such were mainly conducted before year 2000, while more recent 
studies indicated the opposites [16]. A cohort study involved 2 million samples of 
Danish men, reported only weak statistical association between prostatic cancers 
and vasectomy [17]. Likewise, a systematic review of 53 epidemiological studies 
with total samples of more than 2 millions men indicated that the role of vasectomy 
in the development of prostatic cancers was weak if any, and further analysis after 
controlling potential bias indicated that the association did not exist, statistically 
[16]. Other population based study reported no association between vasectomy 
and prostatic cancer [18]. Besides these unclear statistical associations, there have 
not been biological evidence supporting the causal role of vasectomy to prostatic 
cancers [16]. These indicate that being vasectomised are safe from risk of contract-
ing prostatic cancers. However, vasectomised men experienced post operational 
discomforts such as pain, infection, scrotal area swelling and granulomatous 
inflammation of vas deferens [3].
Those limitations of existing contraceptive methods indicate the need to develop 
new procedures. The latest should be effective in preventing pregnancy but ideally 
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acting specifically to reproductive organs, easy in application, eliminating side 
effects, and reversible. The aim of this chapter is to describe the current knowledge in 
regard to antisperm antibody (ASA) contraception and the characteristics of propro-
tein convertase subtilisin/kexin type 4 (PCSK4) as an ASA contraceptive candidate as 
well as to shed light into the direction of future ASA developmental researches.
2. Novel immune-contraceptive methods and the discovery of ASA
With the continued human population growth, its consequential problems and 
limitation of present contraceptive approaches, alternatives methods of contra-
ception have been reported and immune-contraceptive modes has become one 
popular theme. Immuno-contraception is a mean of contraception conducted by 
administering immunogenic substance into human body to induce antibody forma-
tion against particular antigens involved in the conception process [19]. Immuno-
contraceptive agents target at least one of three reproductive physiology pathways 
i.e. preventing gamete production (target antigens: FSH, LH, GnRH), stopping 
embryonic development (target antigen: hCG), or inhibiting gamete function 
(target antigens: Zona Pellucida, spermatozoa) [9].
Vaccine candidates to prevent gamete production have been studied. Heterologous 
ovine LH based vaccine was reported to cause muscle wastage, reduced testicular 
weight and alopecia in monkey [20]. Vaccines against LH were known to elicit 
steroidal side effect and hormonal depression in humans therefore, cannot be used 
for the species [21]. Vaccine against FSH in men inhibited spermatogenesis to oligo-
spermia but not azoospermia, thus only partially affected fertility [21]. A vaccine 
against GnRH has been proven to reduce serum testosterone to castration level and 
has undergone phase II clinical trial to treat prostate carcinoma [22]. However, its use 
for contraception in humans is currently not practical due to feared side effects, such 
as loss of body hair, atrophy of prostate and impotency after chronic exposure [21, 
23]. In contrast, clinical trials on hCG based vaccine have been conducted in women 
from several countries including India, Brazil, Finland, Sweden and Chile under 
the International Committee on Contraception Research of Population Council, 
New York. These trials indicated that the vaccine has no apparent side effects [24]. 
The vaccine has prepared to enter a further phase of clinical trial in India [24].
Inhibition of gamete function, such as debilitating the function of sperm using 
ASA, has also been seen as one promising alternative of immuno-contraceptive 
approach [21, 25–27]. ASA were discovered in 2–30% of either infertile men or in 
their women partners and in 70% of men following vasectomy [21, 25, 28, 29]. ASA 
might become a potential method of immuno-contraceptive in mammals, provided 
that they fulfil a few criteria: (1) Antigens are expressed only in sperm, therefore 
the risk of side effect of cross reaction with other somatic cells will be omitted. (2) 
Antigens are expressed on the outer surface of sperm cell membrane, making them 
highly exposed to antibody recognition. (3) Sperm antigens play roles in fertilisa-
tion process so that the inactivation will impair sperm fertilizability [30].
It has been reported that ASA or other sperm antigen inhibitors could influence 
fertilisation process through at least one of four ways: (1) blocking gamete fusion, 
(2) preventing sperm-zona pellucida binding and penetration, (3) inhibiting acro-
some reaction or (4) immobilising sperm [31–48].
2.1 ASA that block gamete fusion
Zona-free hamster-egg system was used for sperm-egg fusion which is an 
important step of fertilisation process [39]. Using this system, several mammalian 
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sperm antigens have been studied for their role in sperm-oocyte membrane fusion 
including acrosomal protein equatorin (EQT), A disintegrin and metalloproteases 
(ADAMs) family proteins, DE, sperm acrosomal membrane-associated protein 32 
(SAMP32), SAMP14, cluster of differentiation 46 (CD46), human equatorial seg-
ment protein (hESP) and Izumo [31–39].
The EQT is found in various mammalian sperm, including human [40]. 
Equatorin protein is first detected on the budding acrosomal membrane of round 
spermatids, retaining on acrosome during its remodelling in elongating spermatids 
and translocating to the equatorial region of acrosome during the acrosome reac-
tion [40, 41]. Anti-equatorin antibody was reported to block sperm–oocyte fusion 
in-vitro [37]. In other in-vivo study, antibody-containing and control solutions were 
injected directly into the right and left oviductal ampullae, respectively. The results 
revealed that the rates of pregnancy in mice injected with antibody-antiequatorin-
containing solution were significantly lower than that in the control group [37].
The ADAMs (also known as fertilin β) were believed to play some role in fertilisa-
tion of mammalian gametes [31, 42]. Sperm from mice lacking ADAM2 were inca-
pable of binding to egg membrane, migrating inside female reproductive tract and 
binding to the zona pellucida [43]. In human, many ADAMs proteins are expressed in 
many different organs, while many other ADAM genes presents only as pseudogenes 
[42]. However, only three human ADAMs (ADAMs 2, 20 and 30) are specifically 
expressed in testicular tissues. Courtesy of Human Protein Atlas, www.proteinatlas.
org [49]. ADAM2 are expressed in abundant in early and round spermatid, ADAM20 
presents in abundant in late and elongated spermatids and ADAM 30 are expressed in 
cells along seminiferous duct. Courtesy of Human Protein Atlas, www.proteinatlas.
org [49]. However, ADAM2 and ADAM20 are not detected either in the human 
sperm [44] or in ovarian tissue. Courtesy of Human Protein Atlas, www.proteinatlas.
org [49]. These imply that these two human ADAMs could be important in sperm 
maturation but might not be important in human fertilisation process. Further, 
although aforementioned mice study indicated the role of ADAMs in gamete fusion, 
the role of human ADAM30 in fertilisation process remains unclear.
Epididymal glycoprotein DE (37 kDa) of rat is secreted by the epithelium of the 
proximal epididymis and attached to the head of spermatozoa during its transit in 
the epididymis. It participates in the gamete fusion process by binding its ligand on 
the ovum surface [33]. Immunisation of male rats with DE induced specific antibod-
ies and produced a significant reduction in the animal fertility until as low as 0–33% 
as shown by an in-vitro study. The antibody did not interfere with the synthesis or 
secretion of DE, with its attachment to the sperm membrane, or with changes in 
sperm motility, viability, or ability to undergo capacitation and acrosome reaction 
but, antibody against DE debilitated sperm ability to fuse with zona free-egg [33].
The SAMP32, also called sperm acrosome-associated 1 (SPACA1), was expressed 
in the inner membrane of equatorial segment of human sperm acrosome and 
other acrosomal segments [34, 45]. An anti-rSAMP32 was demonstrated to block 
fusion of capacitated human sperm with zona-free hamster eggs in-vitro [34]. 
A study to monitor the outcomes of in-vitro fertilisation (IVF) confirmed that 
the rate of zygotes developed into blastocysts were much lower when the sperms 
weakly expressed SAMP32 on their acrosome, than sperms with high expression 
of SAMP32 [45]. These studies indicate that SAMP32 could prevent conception 
through at least one of two mechanisms i.e. inhibiting gamete fusion or interfering 
zygote development.
Another member of SAMPs family, SAMP14 was shown to be specifically 
expressed in the testis. The protein is localised on outer and inner acrosomal 
membranes and in the acrosomal matrix of human sperm. However, it retains on 
the inner acrosomal membrane after the acrosome reaction. SAMP14 might have a 
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role in gamete interaction, as antibodies anti-recombinant SAMP14 inhibited the 
binding and the fusion of human sperm to zona free hamster eggs in-vitro [35].
Human CD46 is a protein involved in immune response against external anti-
genic exposure [40]. Human CD46 or Membrane Cofactor Protein (MCP) are 
also known to anchor membrane of sperm and involved in fertilisation process. 
Antibodies against MCP significantly inhibited human sperm binding to hamster 
oocytes, in-vitro [36].
The other family of MCP, the CD52 sperm antigen has been detected on the 
mature sperm and seminal plasma; Antibody anti-CD52 showed sperm immobilisa-
tion properties in-vitro. As anti-CD52 is reported to cross react with CD46, CD55 
and CD59 cofactor proteins [46] and because substances are expressed in many 
somatic tissues as humoral immunity agents, their use as contraceptive agent could 
compromise immune system.
hESP is known to localise to the equatorial segment of human sperm. ESP first 
appears in the early phase of acrosomal biogenesis in round spermatids, persists 
during acrosomal maturation and isolated to the edge of the mature acrosome [47]. 
Antisera to recombinant human ESP inhibited both binding of oolemma and fusion 
of human sperm in the hamster egg penetration assay. ESP immunoreacted with 
27% of 15 antisperm antibody (ASA)-positive serum samples from infertile male 
patients and 40% of 5 ASA-positive female sera indicating the possible role of ESP 
in some cases of infertility [38].
Both mouse and human Izumo proteins are detectable on sperm surface only 
after the acrosome reaction. Thus, it was suggested that Izumo is hidden under 
plasma membrane and exposed only after the acrosome reaction occurs. When an 
antibody anti-human Izumo was added to the mixture of mouse sperm and hamster 
egg, no fusion was observed, whereas the fusion was observed in the control assay 
[39]. Izumo1 was hypothesized to act at a molecule designated as Juno, as its recep-
tor on mouse eggs and in other mammals [48].
2.2 ASA that prevent sperm-zona pellucida binding and penetration
A notable sperm antigen that acts in sperm-zona pellucida interaction in mam-
mals is fertilisation antigen-1 (FA-1) [50]. Immunofluorescent reactivity of FA-1 
was detected in acrosome region of human sperm [51]. This protein is known to 
react strongly with 55 kDa Zona Pellucida protein-3 (ZP3) [52]. Zona pellucida 
pre-incubated with human sperm FA-1 failed to bind to sperm, indicated that FA-1 
blocked sperm binding to zona pellucida. Similar blockage was also observed when 
the antibody against FA-1 was pre-incubated with sperm before insemination, 
indicating that the FA-1 is localised on the sperm [50].
In an in-vivo study, female mice injected intradermally with a sperm-specific 
FA-1 DNA vaccine caused a long-term systemic and local immunity resulting in 
anti-fertility effects. The effects were further enhanced when the vaccine was 
mixed with YLP12 DNA vaccine and oligodeoxynucleotide (ODN) [53]. Further 
study suggested that almost half of infertile women studied had circulating anti-
bodies against human FA-1 antigen and YLP12 peptide sequence [54]. The develop-
ment of FA-1 based for male contraceptive vaccine warrants further studies.
2.3. ASA that inhibit acrosome reaction (YLP-12 peptide)
Most of mammalian sperm are incapable of fertilising eggs when ejaculated and 
fertilisation occurs only after an exocytotic process called the acrosome reaction 
[39]. The halts of acrosome reaction thus, might potentially debilitate the compe-
tence of sperm to fertilise egg.
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Two sperm antigens have been studied for this property and for their potential 
to base a development of contraceptive agents; YLP12 and testis specific antigen-1 
(TSA-1). A dodecamer sequence designated YLP12 is a peptide sequence that have 
been identified to specifically localise on the acrosome and tail of spermatozoa 
[55]. It is known to recognise ZP3 component of human ZP proteins, to involve in 
sperm-ZP binding and the antibodies against synthetic 12-mer peptide based on 
YLP12 sequence was reported to specifically inhibit human sperm-ZP binding [56]. 
The antibody anti-YLP12, in other study, was reported to show a concentration-
dependent inhibition of acrosome reaction but did not affect the sperm motility 
[57]. Immunisation of murine model with synthetic YLP12 produced antibodies 
affected fertility by reducing sperm capacitation, acrosome reaction and sperm-
oocyte binding in an in-vitro assay but, immunised murine remained fertile and 
were capable of delivering the equal number of pups compared to control [55]. In 
contrast, other study reported that a sperm-specific YLP12 DNA vaccine injected 
intradermally in female mice caused anti fertility effects [53].
A study reported that TSA-1 is localised to the regions of acrosome, equatorial, 
mid-piece and tail of human sperm. An in-vitro test discovered that TSA-1 concen-
tration-dependently inhibits human sperm acrosome reaction [58].
2.4 Various ASA that immobilise sperm
Sperm tail is widely known as an organelle of motility. Proteomic study showed 
that proteins extracted from tail fraction of sperm can be classified according to their 
functions into two main groups: proteins related to metabolism and energy produc-
tion from endogenous sources, and those related to tail structure and motility [59]. 
These groups however, are at the end function together to support sperm motility.
Epididymal protease inhibitor (Eppin) is expressed in the testis and epididymis 
tissue and on the acrosome and tail of human sperm [60–62]. An in-vitro assay 
showed that the monkey anti-eppin antibodies decreased the progressive motil-
ity of human spermatozoa in terms of distance travelled and speed [62]. Other 
study suggested that blockade of Eppin epitope by anti-eppin antibody would halt 
the acrosome reaction through reduction of ionophore-induced calcium influx 
[60]. Further pre-clinical trial was performed in-vivo in non-human primates and 
showed that Eppin immunised Macaca radiate developed high titers to Eppin (78%) 
and all of these immune-converted monkeys were sterile [63].
Heparin-binding serpin, protein C inhibitor (PCI), is a nonspecific serpin 
that inactivates many plasmatic and extravascular serine proteases. Mutant male 
mice lacking PCI gene are infertile but apparently healthy. Histologic examination 
showed that Sertoli cells and their barrier were destroyed. The resulting sperm are 
malformed, lack of tail and deformed head and immobilised, similar to those seen 
in some cases of men infertility [64], thus the effect of PCI on testicle tissues is 
apparently cytotoxic. In in-vivo fertilisation experiments, only 0.5% (n = 416) eggs 
are fertilised by sperm of mutant male compared to the rate of 92% (n = 415) of 
eggs develop into blastocysts when intact mice is used [64].
The 80 kDa human sperm antigen (HAS) is known to present on the head of the 
human and rat spermatozoa, in the testes and epididymis but not in other somatic 
tissues. Active immunisation of male and female rats with 80 kDa HSA caused 
infertility in all the immunised animals [65]. Further, active immunisation of 
male rabbits, rat and marmosets with synthetic peptide-1 of HSA induced revers-
ible infertility in 100, 100% and 6 of 7 of the respective animals [66]. It strongly 
indicates that antibodies anti-HSA have potential as immuno-contraceptive agents. 
Additionally, anti-HSA antibody induced in-vitro agglutination of human, rat and 
monkey sperm [67].
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Two proteins, A-kinase anchoring protein 3 (AKAP 3) and especially AKAP 
4, are proteins abundantly present in fibrous sheath of mid-piece tail of human 
and mice sperms [68, 69]. AKAP 3 is synthesised earlier during round spermatid 
formation and involves in the arrangement of the basic structure of the sperm tail, 
while AKAP 4 is expressed later during late phase of spermatid formation and plays 
role in the maturation of sperm tail structure [69]. A study showed that male mice 
lacking AKAP4 was not implicated in sperm numbers but, progressive motility of 
its sperm was failed and the male mice were infertile [70].
rSMP-B, following its discovery from mid-piece and tail of rabbit sperm [71], 
was identified to present on the same regions of human sperm [72]. Antibody-anti 
rSMP-B possessed immobilising activities against human and mouse spermatozoa, 
but no agglutinating activity, in-vitro [72].
Lactate dehydrogenase-C4 subunit (LDH-C4) was expressed specifically in 
the testis and most abundant in human sperm. Courtesy of Human Protein Atlas, 
www.proteinatlas.org [49]. Its high activity in the testis is associated with human 
sperm biogenesis and motility [73]. An in-vitro assessment of sperm from LDH-C4 
immunised mature male baboon (Papio sp.) indicated that sperm binding capacity 
to Zona pellucida is reduced in seroconverted animal model [74].
Etomoxir is not an ASA. It is a mitochondrial carnitine palmitoyltransferase 
inhibitor which block serial reaction that transport fatty acid from cytosol into 
intermembrane space of mitochondria, thus halt the oxidation and energy produc-
tion from the substrate [75, 76]. The incubation of sperm with etomoxir results 
in a decreased sperm motility in concentration-dependent manner but does not 
affect the sperm viability [59]. A systemic usage of Etomoxir for contraceptive is 
not applicable, as the substance is hepatotoxic [77]. However, more studies with 
Etomoxir could shed more light of contraceptive targeting sperm antigens respon-
sible for energy production.
3.  PCSK4 as a potential sperm antigen for ASA contraceptive 
developments
3.1 Biochemistry of PCSK4
One sperm antigen potential for development of contraceptive ASA is the pro-
protein convertase subtilisin/kexin type 4 (PCSK4) [78–81]. PCSK4 is an enzyme 
protein expressed in abundant on the outer surface of acrosomal plasma membrane 
of mammalian spermatozoa (Figure 1). It has a molecular weight of 45 kDa [79, 83, 
84]. Biochemically it plays role in the proteolytic activation of precursor proteins 
in the cellular secretory pathway and physiologically it has a specific important 
role in mammalian reproductive process [79, 83–85]. PCSK4 gene is a 9 kilobase 
(kb) DNA, consists of 15 exon and 14 intron which in humans it is located in the 
chromosome 19 [78, 80, 85]. It is a protein associated with bacterial subtilisin and 
yeast kexin where its biosynthesis takes place in endoplasmic reticulum in the form 
of a multi-domain preprotein [78, 80]. PCSK4 is one among nine family members 
of calcium-dependent serin endoproteinase Proprotein Convertase Subtilisin/Kexin 
(PCSK) [79, 83–85]. These nine family members of PCSK are: PCSK1 and PCSK2 
which are expressed in endocrine and neuroendocrine cells; PCSK3, PCSK5, PCSK6 
and PCSK7 are widely expressed by different types of cells; PCSK4 is specifically 
presented by gonadal and placental cells and; PCSK8 and PCSK9 which play roles 
in the synthesis pathways of cholesterol and lipid acid [79, 80, 86–88]. PCSK 1 to 
7 belong to sub-family of kexin while PCSK8 and PCSK9 belong to sub-family of 
pirolysin and proteinase-K, respectively [79, 80, 86]. PCSK 1 to 3 are also known 
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as, consecutively, PC1/3, PC2 and furin, while PCSK 5 to 9 are also recognised as 
PC5/6, PACE4, PC7, SKI-1/SIP and NARC-1, respectively [89].
PCSK4 is synthesised as a zymogen, proPCSK4, in the endoplasmic reticulum [81]. 
Its maturation process remains unclear but suggested to be by an autocatalytic process 
that cleaves the molecule at two sites situated between prodomain and the catalytic 
domain [80]. PCSK4 proprotein contains five domains located consecutively, i.e. the 
signal peptide (SP) domain, prodomain, catalytic domain, a domain of 150 amino 
acids called P (Protease) domain or homo B domain and the C-terminal domain 
which carries transmembrane domain [80]. The SP domain of PCSK4 contains 
signal peptide which directs precursor proteins toward the secretory pathway. The 
Prodomain acts as an intra-molecule chaperone and regulator of the catalytic activity 
of the enzyme, removal of this domain is essential for the activity of the enzyme [90]. 
The primary and secondary cleavage sites of proPCSK4 are situated between prodo-
main and catalytic domain. Catalytic domain of PCSK4 is the active site of the enzyme 
and carries Asp-His-Ser catalytic triad characteristics of serin proteinase [80].
The P domain of PCSK4 plays an important role for proper folding, contains 
beta fold sandwich of galactose bond domain capable of mediating carbohydrates, 
phospholipids or membrane receptors. This P domain acts as a regulator site of 
ultimate enzyme activities under influences of optimum pH and calcium, but also 
in stabilising the structure of catalytic domain [80, 90]. It helps to balance asym-
metric surface at the region of catalytic domain bond, owing to the specific charac-
teristic of multi-basic residues of this enzyme (the consensus of substrate order is 
Arg-X-Lys-Arg-Arg, where X can be an amino acid; the site of peptide dihydrolysis) 
[80, 83, 91]. The C-terminal variable domain influences intracellular localisation, 
in-out recycle of proteins and protein–protein interactions. N-glycosylation sites are 
located at P domain and at C-terminal domain [80].
Expressions of PCSK4 are discovered in abundant in reproductive organs, 
especially in testis. In testis, they can be found in epididymic and germinal cells 
i.e. in acrosomal granules of round spermatids, in acrosomal ridges of elongated 
spermatids and on the acrosomal plasma membrane of spermatozoa [80, 81, 84, 
92]. The PCSK4 or named as proprotein convertase PC4 in a study, is also expressed 
in the human placenta and macrophage-like cells in the ovary [87, 88].
3.2 Physiological roles of PCSK4
Intracellularly, PCSKs takes action in the limited endoproteolytic regulation 
mechanism of the secretory pathway. Limited endoproteolysis constitutes the 
Figure 1. 
Using monoclonal antibody anti-human PCSK4 and rodamin as staining, PCSK4 molecules are detected in 
abundant on the membrane surface of the head of human spermatozoa under Laser Scanning Microscope 
(LSM) examination [82].
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post-translational modifications of proteins by which cells diversify and regulate 
gene products [78]. Endoproteolytic process occurs during modifications to activate 
many precursor proteins in biological cell functions including zymogen activations, 
formations of peptide hormones, complement activations, blood clotting and blood 
clot lysing, angiogenesis and tissue re-modelling. Secretory pathway processes of 
eukaryotic cells are mainly assisted by carboxyl residues of Lys or Arg (P1) in the 
order R/K – (X)n – X/K/R – R (where: X = amino acids other than Cys; n = 1, 3, or 5; 
K or R = the place of P2 amino acid) [78, 86, 91].
PCSK4 present in acrosome region of sperm thus, is hypothesised to play role 
in capacitation and acrosome reaction [80, 84]. SPCSK4-null sperm has normal 
appearance, normal motility competence and undergo normal capacitation process 
but, following capacitation they suffer reduced hyperactivated motility [93]. Post-
capacitation hyperactivity is a qualitative characteristics of sperm which thought 
to be important to assist sperm penetrating zona pellucida of an egg. PCSK4-null 
sperms show a reduced fertilisation competence in-vitro and the embryo resulted 
from PCSK4-null sperm fails to develop further [93].
3.3 Substrates of PCSK4
Two molecules have been known as the natural substrates of PCSK4; pro-
pituitary adenylate cyclase-activating protein (proPACAP) and Insulin-like growth 
factor II (IGF-II) [87, 94]. The proPACAP has two active isoforms; PACAP38 and 
PACAP27 residues. PACAPs are expressed in hypothalamus, in extra-hypothalamic 
regions of the brain, in the granulosa cells of the developing ovarian follicles of 
the rat and transiently in rat spermatid cap but, are absent at the other stages of 
spermatogenesis. They are also expressed in Sertoli cells and Leydig cells. Gonadal 
PCSK4 is the only enzyme that activates proPACAP both in the testis and the ovary 
of the mice [94]. A study reported that PACAP null female mice failed to implant its 
embryo to the uterus [95], suggesting proPACAP activation conducted by PCSK4 
is pivotal in embryonic implantation. PCSK4 null male mice lack of PACAP activa-
tion and produce normal but incompetent sperm. It leads to the hypothesised that 
PACAP may not important in maturation process of the sperm but involves in the 
production of molecules required for the functional mature sperm [94].
Other substrate of PCSK4, IGF-II, is discovered in placenta and its inactivity has 
been shown to be involved in the pathophysiology of intrauterine growth restriction 
(IUGR) of human foetus; a major cause of perinatal death. In this pathway, Placental 
PCSK4 activates pro-IGF-II to form a half-matured IGF-II and successively mature 
IGF-II as a result of the cleavage of its terminal basic residues by carboxypeptidases 
[87]. Inhibition of Placental PCSK4 by a PCSK4-specific inhibitor blocks pro-IGF-II 
processing resulting a reduced trophoblast cell migration [87], likely due to reduced 
effectivity of trans-placental diffusional exchange leading to reduced nutritional supply 
[96]. The locality and functionality of the two substrates of PCSK4 indicate that PCSK4 
are physiologically important during zona penetration and embryonic development.
3.4 Inhibitors of PCSK4
Studies in model animals showed that individuals with PCSK4 expression 
disorder have significantly lower fertilisation capability [79]. In our study, intact 
male Rattus norvegicus previously injected with antibody anti-PCSK4 was allowed 
to fertile female rats and it showed that the number of off-springs delivered by 
these female rats significantly declined in accordance with the increased doses of 
antibody anti-PCSK4 injected [82]. These indicate that inactivation of PCSK4 by 
injectable anti-PCSK4 could prevent conception.
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The use of synthetic PCSK4 inhibitors could also serve as an option for contra-
ception. A synthetic inhibitor of PCSK has been developed based on the knowledge, 
that prodomain removal is essential for activation of the enzyme. Binding of this 
domain to PCSK4 active enzyme could hypothetically inactivate the enzyme. A 
peptide, mimicking prodomain sequence near its primary activation site, was 
engineered and an in-vitro assay using a recombinant PCSK4 showed that PCSK4-
mediated proteolysis was efficiently blocked by synthetic prodomain rPC4101–116 
peptide [90].
Other potent synthetic PCSK4-inhibitors: tetrapeptide chloromethyl ketone and 
the Dec-RVKR/K-cmk (Decanoyl-RVKR/K-chloromethyl ketone) were reported 
to inhibit PCSK4 more potently than synthetic prodomain rPC4101–116 peptide [90]. 
Another substance, synthetic enediyne amino acid containing peptides, was devel-
oped and reported to inhibit PCSK4 activity in-vitro [97]. Further, dimeric form of 
CRES was reported to moderately block the PCSK4 activity to human proIGF-2 in 
human placental trophoblast cell line [98].
4. Future development of ASA contraceptives
Only a few of aforementioned ASA underwent animal models in-vivo study. 
Among are EQT, FA-1, YLP12, Eppin, PCI, HSA, AKAP 4 and PCSK4. None of these 
molecules however, shows full inhibition of fertilisation in animal models, whereas 
YLP12 contraceptive studies reported various results from partial to lack of inhibi-
tion of fertility to animal models [37, 53, 63–65, 82] [53, 55, 70]. Therefore, further 
efforts are needed to make ASA contraceptive become reality.
Future development of ASA contraceptives might include the studies of under-
explored proteins such as those involve in the energy production in the mitochon-
dria of sperm. Proteomic approach assistance, in this regard, have enabled the 
discovery of large number of novel proteins [59] and allows further investigations 
of single protein of interest.
On the other hand, as the usage of single molecule have been impractical, 
alternative of future ASA development might include the study of efficacy of 
multivalent vaccines, in order to boost the final effective contraception effect 
as well as reducing potential toxic effect of high dose administration of a single 
substance. Study of multivalent vaccine targeting proteins of acrosomal sperm 
has been actually initiated. In the study, immunised monkeys recognised the five 
antigens used: ESP, SLLP-1, SAMP 32, SP-10 and SAMP 14, with the highest IgG 
average absorbance values were to ESP, SAMP 32 and SP-10 but at IgG lower values 
for SLLP-1 and SAMP 14 [99]. Further, capacitated sperm treated with sera from 
immunised monkeys showed fusion inhibition but only in two of five individuals 
[99]. This was a sound study that used proteins which were pre-tested to not cross 
react to each other. But the study used molecules that never had undergone in-vivo 
study so individual effect of the vaccine component was unknown. In addition, a 
study of FA-1 and YLP12 mixed vaccine in mice further support the more potential 
of multivalent vaccine in inducing contraceptive effects compared to monovalent 
vaccine [54].
The in-vivo study of anti-PSCK4 administration demonstrated in our laboratory 
indicates that it is possible to efficaciously administer contraceptive agents in the 
form of antiserum rather than injecting them to an individual for a few times as 
immunisation [82]. In the future, this approach might be more practical if the mol-
ecule could reach therapeutic concentration in the seminal plasma once the semen 
ejaculated thus well mixed with sperm along their journey to egg, mimicking in-vitro 
incubation of sperm with its inhibitors prior to a fertilisation challenge with eggs.
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Topical applications such as intravaginal administration might be strategy of 
choice in the antisperm contraceptive application especially for molecules which 
have been known to be toxic when administered systemically such as etomoxir. 
Topical intra-ampullar oviduct administration of antisperm agent in animal model 
has proven that topical ASA contraceptive application can be efficacious [37].
5. Conclusions
Existing contraceptive methods have been widely practiced by couples globally. 
However, some side effects limit the broader utilisation. Although ASA is a promis-
ing method of contraception it is not yet practical. More studies should be done in 
order to enable ASA to replace common contraceptive methods.
Acknowledgements
Authors would like to thank to Biochemistry Laboratory of University of 
Brawijaya for the provision of facilities that allows the writing of this manuscript.
Conflict of interest
We authors declare that there is no conflict of interest related to the preparation 
of this manuscript.
Author details
Dahril Dahril1, Widi Nugroho2 and Aulanni’am Aulanni’am3*
1 Sub Division of Urology, Faculty of Medicine, Zainoel Abidin Hospital, Syiah 
Kuala University, Banda Aceh, Indonesia
2 Laboratory of Veterinary Public Health, Faculty of Veterinary Medicine, 
University of Brawijaya, Malang, East Java, Indonesia
3 Laboratorium of Biochemistry, Faculty of Veterinary Medicine, University of 
Brawijaya, Malang, East Java, Indonesia
*Address all correspondence to: aulani@ub.ac.id
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
12
Innovations in Assisted Reproduction Technology
References
[1] Crosigani P. Hormonal contraseption: 
What is new? Human Reproduction 
Update. 2002;8(4):359-371
[2] Division UNP. World Population 
Prospects the 2010 Revision. United 
Nations Population Division: New York, 
United Nations; 2010
[3] Page ST, Amory JK, Bremner WJ. 
Advances in male contraception. 
Endocrine Reviews. 2008;29(4):465-493
[4] Division UNP. World Population 
Prospects the 2000 Revision. United 
Nations Population Division: New York, 
United Nations; 2000
[5] Suri A. Sperm-based contraceptive 
vaccines: Current status, merits and 
development. Expert Reviews in 
Molecular Medicine. 2005;7(18):1-16
[6] Boserup E. The Conditions of 
Agricultural Growth: The Economics 
of Agrarian Change under Population 
Pressure. New York: Routledge; 2017
[7] DeFries RS, Rudel T, Uriarte M, 
Hansen M. Deforestation driven by urban 
population growth and agricultural 
trade in the twenty-first century. Nature 
Geoscience. 2010;3(3):178
[8] Coccia M. General causes of 
terrorism: High population growth 
in problematic society. 2017. 
Available at SSRN: https://ssrn.com/
abstract=2951293
[9] Naz RK. Antisperm immunity for 
contraception. Journal of Andrology. 
2006;27(2):153-159
[10] Glasier A. Acceptability of 
contraception for men: A review. 
Contraception. 2010;82(5):453-456
[11] Meriggiola MC, Costantino A, 
Cerpolini S, Bremner WJ, Huebler D, 
Morselli-Labate AM, et al. Testosterone 
undecanoate maintains spermatogenic 
suppression induced by cyproterone 
acetate plus testosterone undecanoate 
in normal men. The Journal of Clinical 
Endocrinology and Metabolism. 
2003;88(12):5818-5826
[12] Baird DT, Glasier AF. Science, 
medicine, and the future. Contraception. 
BMJ. 1999;319(7215):969-972
[13] Lara-Torre E, Spotswood L, 
Correia N, Weiss PM. Intrauterine 
contraception in adolescents and young 
women: A descriptive study of use, 
side effects, and compliance. Journal of 
Pediatric and Adolescent Gynecology. 
2011;24(1):39-41
[14] Meriggiola M, Marcovina S, 
Paulsen C, Bremner W. Testosteron 
enanthate at the dose 200 mg/week 
decreases hdl-cholesterol levels in 
healthy men. International Journal of 
Andrology. 2006;18:237-242
[15] Namekawa T, Imamoto T, Kato M, 
Komiya A, Ichikawa T. Vasovasostomy 
and vasoepididymostomy: Review 
of the procedures, outcomes, 
and predictors of patency and 
pregnancy over the last decade. 
Reproductive Medicine and Biology. 
2018;17(4):343-355
[16] Bhindi B, Wallis CJD, 
Nayan M, Farrell AM, Trost LW, 
Hamilton RJ, et al. The association 
between vasectomy and prostate 
Cancer: A systematic review and 
meta-analysisThe association between 
vasectomy and prostate Cancer the 
association between vasectomy and 
prostate Cancer. JAMA Internal 
Medicine. 2017;177(9):1273-1286
[17] Husby A, Wohlfahrt J, Melbye M. 
Vasectomy and Prostate Cancer Risk: 
A 38-Year Nationwide Cohort Study. 
Journal of the National Cancer Institute. 
2020;112(1):djz099
13
Human Contraceptives: Current Status, Sperm Antigen Inhibitors and an Insight into PCSK4
DOI: http://dx.doi.org/10.5772/intechopen.89721
[18] Nayan M, Hamilton RJ, 
Macdonald EM, Li Q , Mamdani MM, 
Earle CC, et al. Vasectomy and risk 
of prostate cancer: Population based 
matched cohort study. BMJ. 
2016;355:i5546
[19] Yatim W. Reproduksi dan 
Embriologi. ke-3 ed. Bandung: Tarsito; 
1994
[20] Moudgal N, Jeyakumar M, 
Krishnamurthy H, Sridhar S, 
Krihsnamurthy H, Martin F. 
Development of male contraceptive 
vaccine - a perspective. 
Human Reproduction Update. 
1997;3(4):335-346
[21] Naz R. Immunization with sperm 
antigens to induce contraception. In: 
Krause WKH, Naz RK, editors. Immune 
Infertility. Berlin Heidelberg: Springer; 
2009. pp. 197-207
[22] Talwar GP, Vyas HK, Purswani S, 
Gupta JC. Gonadotropin-releasing 
hormone/human chorionic 
gonadotropin β based recombinant 
antibodies and vaccines. Journal 
of Reproductive Immunology. 
2009;83(1):158-163
[23] Kaur K, Prabha VJ. 
Immunocontraceptives: New approaches 
to fertility control. BioMed Research 
International. 2014;2014:868196
[24] Talwar GP, Nand KN, Gupta JC,  
Bandivdekar AH, Sharma RS, 
Lohiya NK. Current status of a unique 
vaccine preventing pregnancy. Frontiers 
in Bioscience. 2017;9:321-332
[25] Naz RK. Antisperm contraceptive 
vaccines: Where we are and where we are 
going? American Journal of Reproductive 
Immunology. 2011;66(1):5-12
[26] Gupta S, Bansal P. Vaccines for 
immunological control of fertility. 
Reproductive Medicine and Biology. 
2010;9(2):61-71
[27] Naz RK. Contraceptive vaccines: 
Success, status, and future perspective. 
American Journal of Reproductive 
Immunology. 2011;66(1):2-4
[28] Chamley LW, Clarke GN. Antisperm 
antibodies and conception. Seminars in 
Immunopathology. 2007;29(2):169-184
[29] Naz RK. Human synthetic peptide 
vaccine for contraception targeting 
sperm. Archives of Andrology. 
2004;50(2):113-119
[30] Frayne J, Hall L. The potential 
use of sperm antigens as targets for 
immunocontraception; past, present 
and future. Journal of Reproductive 
Immunology. 1999;43(1):1-33
[31] Naz RK. Antisperm contraceptive 
vaccine. In: Immune Infertility. 
Switzerland: Springer; 2017. pp. 249-261
[32] Primakoff P, Myles DG. Cell–cell 
membrane fusion during mammalian 
fertilization. FEBS Letters. 
2007;581(11):2174-2180
[33] Ellerman DA, Brantúa VS, 
Martínez SP, Cohen DJ, Conesa D, 
Cuasnicú PS. Potential contraceptive 
use of epididymal proteins: 
Immunization of male rats with 
epididymal protein DE inhibits sperm 
fusion ability. Biology of Reproduction. 
1998;59(5):1029-1036
[34] Hao Z, Wolkowicz MJ, Shetty J, 
Klotz K, Bolling L, Sen B, et al. SAMP32, 
a testis-specific, isoantigenic sperm 
acrosomal membrane-associated 
protein. Biology of Reproduction. 
2002;66(3):735-744
[35] Shetty J, Wolkowicz MJ, Digilio LC, 
Klotz KL, Jayes FL, Diekman AB, et al. 
SAMP14, a novel, acrosomal membrane-
associated, glycosylphosphatidylinositol-
anchored member of the Ly-6/
urokinase-type plasminogen 
activator receptor superfamily with 
a role in sperm-egg interaction. The 
Innovations in Assisted Reproduction Technology
14
Journal of Biological Chemistry. 
2003;278(33):30506-30515
[36] Anderson DJ, Abbott AF, 
Jack RM. The role of complement 
component C3b and its receptors in 
sperm-oocyte interaction. Proceedings 
of the National Academy of Sciences. 
1993;90(21):10051-10055
[37] Yoshinaga K, Saxena D, Oh-Oka T, 
Tanii I, Toshimori K. Inhibition of 
mouse fertilization in vivo by intra-
oviductal injection of an anti-equatorin 
monoclonal antibody. Reproduction. 
2001;122(4):649-655
[38] Wolkowicz M, Digilio L, Klotz K, 
Shetty J, Flickinger C, Herr J. Equatorial 
segment protein (ESP) is a human 
alloantigen involved in sperm-egg 
binding and fusion. Journal of 
Andrology. 2008;29(3):272-282
[39] Inoue N, Ikawa M, Isotani A, 
Okabe M. The immunoglobulin 
superfamily protein Izumo is required 
for sperm to fuse with eggs. Nature. 
2005;434(7030):234
[40] Inoue N, Ikawa M, Okabe M. The 
mechanism of sperm-egg interaction 
and the involvement of IZUMO1 in 
fusion. Asian Journal of Andrology. 
2011;13(1):81-87
[41] Ito C, Yamatoya K, Yoshida K, 
Fujimura L, Hatano M, Miyado K, 
et al. Integration of the mouse sperm 
fertilization-related protein 
equatorin into the acrosome during 
spermatogenesis as revealed by 
super-resolution and immunoelectron 
microscopy. Cell and Tissue Research. 
2013;352(3):739-750
[42] Cho C. Mammalian ADAMs 
with Testis-Specific or-Predominant 
Expression. In: N.M. Hooper, U. 
Lendeckel, editors. The ADAM Family 
of Proteases. US, Boston, MA: Springer; 
2005. pp. 239-59
[43] Cho C, Bunch DOD, Faure J-E, 
Goulding EH, Eddy EM, Primakoff P, 
et al. Fertilization defects in sperm 
from mice lacking fertilin β. Science. 
1998;281(5384):1857-1859
[44] Choi H, Jin S, Kwon JT, Kim J, 
Jeong J, Kim J, et al. Characterization 
of mammalian ADAM2 and its absence 
from human sperm. PLoS One. 
2016;11(6):e0158321
[45] Kishida K, Harayama H, Kimura F, 
Murakami T. Individual differences in 
the distribution of sperm acrosome-
associated 1 proteins among male 
patients of infertile couples; their 
possible impact on outcomes of 
conventional in vitro fertilization. 
Zygote. 2016;24(5):654-661
[46] Hasegawa A, Shigeta M, 
Shibahara H. Sperm immobilizing 
antibody and its target antigen. In: 
Immune Infertility. Switzerland: 
Springer; 2017. pp. 173-184
[47] Wolkowicz MJ, Shetty J, 
Westbrook A, Klotz K, Jayes F, 
Mandal A, et al. Equatorial segment 
protein defines a discrete Acrosomal 
subcompartment persisting throughout 
Acrosomal Biogenesis1. Biology of 
Reproduction. 2003;69(3):735-745
[48] Bianchi E, Doe B, Goulding D,  
Wright GJ. Juno is the egg Izumo 
receptor and is essential for 
mammalian fertilization. Nature. 
2014;508(7497):483
[49] Uhlén M, Fagerberg L, 
Hallström BM, Lindskog C, Oksvold P, 
Mardinoglu A, et al. Tissue-based map 
of the human proteome. Science. 
2015;347(6220):1260419
[50] Kadam AL, Fateh M, Naz RK. 
Fertilization antigen (FA-1) completely 
blocks human sperm binding to human 
zona pellucida: FA-1 antigen may be 
a sperm receptor for zona pellucida 
15
Human Contraceptives: Current Status, Sperm Antigen Inhibitors and an Insight into PCSK4
DOI: http://dx.doi.org/10.5772/intechopen.89721
in humans. Journal of Reproductive 
Immunology. 1995;29(1):19-30
[51] Naz R, Rosenblum B, Menge A. 
Characterization of a membrane antigen 
from rabbit testis and sperm isolated by 
using monoclonal antibodies and effect 
of its antiserum on fertility. Proceedings 
of the National Academy of Sciences. 
1984;81(3):857-861
[52] Naz R, Ahmad K. Molecular 
identities of human sperm proteins that 
bind human zona pellucida: Nature 
of sperm-zona interaction, tyrosine 
kinase activity, and involvement of 
FA-1. Molecular Reproduction and 
Development. 1994;39(4):397
[53] Naz RK. Effect of fertilization 
antigen (FA-1) DNA vaccine on 
fertility of female mice. Molecular 
Reproduction and Development. 
2006;73(11):1473-1479
[54] Williams J, Samuel A, Naz RK. 
Presence of Antisperm antibodies 
reactive with peptide epitopes 
of FA-1 and YLP12 in sera of 
Immunoinfertile women. American 
Journal of Reproductive Immunology. 
2008;59(6):518-524
[55] Naz RK, Chauhan SC. Human 
sperm-specific peptide vaccine 
that causes long-term reversible 
Contraception1. Biology of 
Reproduction. 2002;67(2):674-680
[56] Zhu X, Naz RK, Kadam AL. 
Identification of human sperm peptide 
sequence involved in egg Bindingfor 
Immunocontraception1. Biology of 
Reproduction. 2000;62(2):318-324
[57] Naz RK, Chauhan S, 
Trivedi R.Monoclonal antibody against 
human sperm-specific YLP 12 
peptide sequence involved in oocyte 
binding. Archives of Andrology. 
2002;48(3):169-175
[58] Santhanam R, Naz RK. Novel human 
testis-specific cDNA: Molecular cloning, 
expression and immunobiological 
effects of the recombinant protein. 
Molecular Reproduction and 
Development. 2001;60(1):1-12
[59] Amaral A, Castillo J, Estanyol JM, 
Ballescà JL, Ramalho-Santos J, Oliva R. 
Human sperm tail proteome suggests 
new endogenous metabolic pathways. 
Molecular & Cellular Proteomics. 
2013;12(2):330-342
[60] Zhang J, Ding X, Bian Z, Xia Y, 
Lu C, Wang S, et al. The effect of anti-
eppin antibodies on ionophore A23187-
induced calcium influx and acrosome 
reaction of human spermatozoa. Human 
Reproduction. 2009;25(1):29-36
[61] Richardson RT, Sivashanmugam P, 
Hall SH, Hamil KG, Moore PA, 
Ruben SM, et al. Cloning and 
sequencing of human Eppin: A novel 
family of protease inhibitors expressed 
in the epididymis and testis. Gene. 
2001;270(1):93-102
[62] Widgren EE, Richardson RT, 
O'Rand MG, Beyler S. Inhibition of 
human sperm motility by contraceptive 
anti-Eppin antibodies from infertile 
male monkeys: Effect on cyclic 
adenosine Monophosphate1. Biology of 
Reproduction. 2009;80(2):279-285
[63] O’rand M, Widgren E,  
Sivashanmugam P, Richardson R,  
Hall S, French F, et al. Reversible 
immunocontraception in male monkeys 
immunized with eppin. Science. 
2004;306(5699):1189-1190
[64] Uhrin P, Dewerchin M, 
Hilpert M, Chrenek P, Schöfer C, 
Zechmeister-Machhart M, et al. 
Disruption of the protein C 
inhibitor gene results in impaired 
spermatogenesis and male infertility. 
The Journal of Clinical Investigation. 
2000;106(12):1531-1539
Innovations in Assisted Reproduction Technology
16
[65] Bandivdekar AH, Vernekar VJ, 
Moodbidri SB, Koide SS. Characterization 
of 80 kDa human sperm antigen 
responsible for Immunoinfertility. 
American Journal of Reproductive 
Immunology. 2001;45(1):28-34
[66] Khobarekar BG, Vernekar V, 
Raghavan V, Kamada M, Maegawa M, 
Bandivdekar AH. Evaluation of the 
potential of synthetic peptides of 
80 kDa human sperm antigen (80 
kDaHSA) for the development of 
contraceptive vaccine for male. Vaccine. 
2008;26(29-30):3711-3718
[67] Vernekar VJ, Bandivdekar AH, 
Raghavan VP, Kamada M, Koide SS. 
Studies with synthetic peptides of 
80 kDa human sperm antigen 
(80 kDa HSA). American Journal 
of Reproductive Immunology. 
2004;51(2):106-111
[68] TURNER RM, MUSSE MP, 
Mandal A, Klotz K, JAYES FC, HERR 
JC, et al. Molecular genetic analysis 
of two human sperm fibrous sheath 
proteins, AKAP4 and AKAP3, in 
men with dysplasia of the fibrous 
sheath. Journal of Andrology. 
2001;22(2):302-315
[69] Brown PR, Miki K, Harper DB, 
Eddy EM. A-kinase anchoring protein 
4 binding proteins in the fibrous sheath 
of the sperm flagellum. Biology of 
Reproduction. 2003;68(6):2241-2248
[70] Miki K, Willis WD, Brown PR, 
Goulding EH, Fulcher KD, Eddy EM. 
Targeted disruption of the Akap4 
gene causes defects in sperm flagellum 
and motility. Developmental Biology. 
2002;248(2):331-342
[71] Wang L, Miao S, Cao S, Wu B, 
Koide S. Isolation and characterization 
of a rabbit sperm tail protein. Archives 
of Andrology. 1986;16(1):55-66
[72] Takikawa M, Kamada M, 
Maegawa M, Yamano S, Irahara M, 
Aono T, et al. Evaluation of two sperm 
antigens, rSMP-B and YWK-II, as 
targets for immunocontraception. 
Zygote. 2001;9(2):145-151
[73] Sawane MV, Kaore SB,  
Gaikwad RD, Patil PM, Patankar SS,  
Deshkar AM. Seminal LDH-C4 
isoenzyme and sperm mitochondrial 
activity: A study in male partners of 
infertile couples. Indian Journal of 
Medical Sciences. 2002;56(11):560-566
[74] Goldberg E, VandeBerg JL, 
Mahony MC, Doncel GF. Immune response 
of male baboons to testis-specific 
LDH-C4☆☆this work was supported by 
contraceptive Research and Development 
(CONRAD) program CICCR Grant 
#640510 to Northwestern University 
and by NIH Grant P51RR13986 to the 
southwest regional primate research 
center. The views expressed by the 
authors do not necessarily reflect those of 
the CONRAD program. Contraception. 
2001;64(2):93-98
[75] Schmidt-Schweda S, 
Holubarsch C. First clinical trial with 
etomoxir in patients with chronic 
congestive heart failure. Clinical 
Science. 2000;99(1):27-35
[76] Ferrick DA, Neilson A, 
Beeson C. Advances in measuring 
cellular bioenergetics using extracellular 
flux. Drug Discovery Today. 
2008;13(5-6):268-274
[77] Holubarsch CJ, Rohrbach M, 
Karrasch M, Boehm E, Polonski L, 
Ponikowski P, et al. A double-blind 
randomized multicentre clinical trial 
to evaluate the efficacy and safety of 
two doses of etomoxir in comparison 
with placebo in patients with moderate 
congestive heart failure: The ERGO 
(etomoxir for the recovery of glucose 
oxidation) study. Clinical Science. 
2007;113(4):205-212
[78] Gyamera-Acheampong C, 
17
Human Contraceptives: Current Status, Sperm Antigen Inhibitors and an Insight into PCSK4
DOI: http://dx.doi.org/10.5772/intechopen.89721
subtilisin/kexin type 4 in mammalian 
fertility: A review. Human Reproduction 
Update. 2009;15(2):237-247
[79] Gyamera-Acheampong C, 
Tantibhedhyangkul J, 
Weerachatyanukul W, Tadros H, 
Xu H, van de Loo JW, et al. Sperm 
from mice genetically deficient for the 
PCSK4 proteinase exhibit accelerated 
capacitation, precocious acrosome 
reaction, reduced binding to egg zona 
pellucida, and impaired fertilizing 
ability. Biology of Reproduction. 
2006;74(4):666-673
[80] Acheampong CG. The Physiology 
and Biochemistry of the Fertility 
Enzyme Proprotein Convertase 
Subtilisin/Kexin Type 4. Ottawa 
Canada: University of Ottawa; 2009
[81] Gyamera-Acheampong C, Sirois F, 
Denis NJ, Mishra P, Figeys D, Basak A, 
et al. The precursor to the germ cell-
specific PCSK4 proteinase is inefficiently 
activated in transfected somatic cells: 
Evidence of interaction with the BiP 
chaperone. Molecular and Cellular 
Biochemistry. 2011;348(1-2):43-52
[82] Simanjuntak D. Pengaruh Antibodi 
Convertase Tipe 4 (PCSK4) Membran 
Plasma Akrosom Spermatozoa Manusia 
Terhadap Hambatan kemampuan 
Fertilisasi In Vitro dan In Vivo pada 
Tikus (Rattus norvegicus) [PhD]. 
Surabaya, Indonesia: Airlangga 
University; 2016
[83] Seidah NG. The proprotein 
convertases, 20 years later. Methods in 
Molecular Biology. 2011;768:23-57
[84] Dahril D, Aulanni'am A, 
Hilmanto D, Purwatiningsih W. The 
characterization of proprotein 
convertase subtilisin/kexin 
type4 (PCSK4) on human sperm 
membran for developping male 
immunocontraception candidates. 
International Journal of ChemTech 
Research. 2014;5:2229-2234
[85] Seidah N, Prat A. Precursor 
convertases in the secretory pathway, 
cytosol and extracellular milieu. Essays 
in Biochemistry. 2002;38:79-94
[86] Basak A, Touré BB, Lazure C, 
Mbikay M, Chrétien M, Seidah NG. 
Enzymic characterization in vitro of 
recombinant proprotein convertase 
PC4. The Biochemical Journal. 
1999;343(Pt 1):29-37
[87] Qiu Q , Basak A, Mbikay M, 
Tsang BK, Gruslin A. Role of pro-
IGF-II processing by proprotein 
convertase 4 in human placental 
development. Proceedings of the 
National Academy of Sciences. 
2005;102(31):11047-11052
[88] Tadros H, Chrétien M, Mbikay M. 
The testicular germ-cell protease PC4 is 
also expressed in macrophage-like cells 
of the ovary. Journal of Reproductive 
Immunology. 2001;49(2):133-152
[89] Gyamera-Acheampong C, 
Vasilescu J, Figeys D, Mbikay M. PCSK4-
null sperm display enhanced protein 
tyrosine phosphorylation and ADAM2 
proteolytic processing during in vitro 
capacitation. Fertility and Sterility. 
2010;93(4):1112-1123
[90] Basak A, Shervani NJ, Mbikay M, 
Kolajova M. Recombinant proprotein 
convertase 4 (PC4) from Leishmania 
tarentolae expression system: 
Purification, biochemical study and 
inhibitor design. Protein Expression and 
Purification. 2008;60(2):117-126
[91] Bergeron F, Leduc R, Day R. 
Subtilase-like pro-protein convertases: 
From molecular specificity to 
therapeutic applications. Journal 
of Molecular Endocrinology. 
2000;24:1-22
[92] Mishra P. Study of Inhibitor Effect 
of Epididymal CRES on PC4/PCSK4 
Activity [Science]. Ottawa, Ontario, 
Canada: University of Ottawa; 2011
Innovations in Assisted Reproduction Technology
18
[93] Mbikay M, Tadros H, Ishida N, 
Lerner C, Lamirande ED, Chen A, et al. 
Impaired fertility in mice deficient for 
the testicular germ-cell protease PC4. 
Proceedings of the National Academy 
of Sciences of the United States of 
America. 1997;94:6842-6846
[94] Li M, Mbikay M, Arimura A. 
Pituitary Adenylate Cyclase-activating 
polypeptide precursor is processed 
solely by Prohormone Convertase 
4 in the gonads. Endocrinology. 
2000;141:3723-3730
[95] Isaac ER, Sherwood NM. Pituitary 
adenylate cyclase-activating 
polypeptide (PACAP) is important 
for embryo implantation in mice. 
Molecular and Cellular Endocrinology. 
2008;280(1):13-19
[96] Sibley C, Coan P, Ferguson- 
Smith A, Dean W, Hughes J, Smith P, 
et al. Placental-specific insulin-like 
growth factor 2 (Igf2) regulates the 
diffusional exchange characteristics 
of the mouse placenta. Proceedings 
of the National Academy of Sciences. 
2004;101(21):8204-8208
[97] Basak A, Goswami M, Rajkumar A, 
Mitra T, Majumdar S, O’Reilly P, et al. 
Enediynyl peptides and iso-coumarinyl 
methyl sulfones as inhibitors of 
proprotein convertases PCSK8/SKI-1/
S1P and PCSK4/PC4: Design, synthesis 
and biological evaluations. Bioorganic 
& Medicinal Chemistry Letters. 
2015;25(10):2225-2237
[98] Mishra P, Qiu Q , Gruslin A, 
Hidaka Y, Mbikay M, Basak A. In vitro 
regulatory effect of epididymal 
serpin CRES on protease activity 
of proprotein convertase PC4/
PCSK4. Current Molecular Medicine. 
2012;12(8):1050-1067
[99] Kurth BE, Digilio L, Snow P, 
Bush LA, Wolkowicz M, Shetty J, et al. 
Immunogenicity of a multi-component 
recombinant human acrosomal protein 
vaccine in female Macaca fascicularis. 
Journal of Reproductive Immunology. 
2008;77(2):126-141
